Hiroaki Ida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hiroaki Ida has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Katsumi Eguchi
Nagasaki University
14 shared publications - Atsushi Kawakami
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences
12 shared publications - Mami Tamai
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
12 shared publications - Kazuhiko Arima
Department of Public Health Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
11 shared publications - Tomoki Origuchi
Nagasaki University Graduate School of Biomedical Sciences
9 shared publications - Hideki Nakamura
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan
8 shared publications
Latest Publications
- 6 March 2014
- Published by Wiley in International Journal of Dermatology
- Vol. 53 (7) , e361-e363
Successful treatment of Schnitzler syndrome with cyclosporine
- 6 March 2014
- Published by Wiley in International Journal of Dermatology
- Vol. 53 (7) , e361-e363
Successful treatment of Schnitzler syndrome with cyclosporine
- 6 June 2012
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 23 (2) , 254-259
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach
Objective To identify the value of magnetic resonance imaging (MRI)-proven bone edema in patients with very early rheumatoid arthritis (RA). Methods All of the 13 patients included in the study were positive at entry for MRI-proven bone edema of the wrist and finger joints and anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. A tight control approach was applied for 12 months. Plain MRI and radiographs of both wrist and finger joints were examined every 6 months. MRI was scored by the RA MRI scoring (RAMRIS) technique and plain radiographs were scored using the Genant-modified Sharp score. Variables that were correlated with plain radiographic changes at 12 months were examined. Results Simplified disease activity index (SDAI) remission was achieved in 7 patients, and a significant reduction in the RAMRIS bone edema score, which declined to < 33 % as compared with the baseline, was achieved in 8 out of 13 patients. Four patients showed plain radiographic progression while 9 patients did not. Significant reductions in the RAMRIS bone edema score (p = 0.007) and the time-integrated SDAI (p = 0.031) were the variables involved in plain radiographic progression. Conclusions Improvement in bone edema may be associated with protection against structural damage in very early RA patients managed using the tight control approach.
- 6 June 2012
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 23 (2) , 254-259
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach
Objective To identify the value of magnetic resonance imaging (MRI)-proven bone edema in patients with very early rheumatoid arthritis (RA). Methods All of the 13 patients included in the study were positive at entry for MRI-proven bone edema of the wrist and finger joints and anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. A tight control approach was applied for 12 months. Plain MRI and radiographs of both wrist and finger joints were examined every 6 months. MRI was scored by the RA MRI scoring (RAMRIS) technique and plain radiographs were scored using the Genant-modified Sharp score. Variables that were correlated with plain radiographic changes at 12 months were examined. Results Simplified disease activity index (SDAI) remission was achieved in 7 patients, and a significant reduction in the RAMRIS bone edema score, which declined to < 33 % as compared with the baseline, was achieved in 8 out of 13 patients. Four patients showed plain radiographic progression while 9 patients did not. Significant reductions in the RAMRIS bone edema score (p = 0.007) and the time-integrated SDAI (p = 0.031) were the variables involved in plain radiographic progression. Conclusions Improvement in bone edema may be associated with protection against structural damage in very early RA patients managed using the tight control approach.
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (Suppl) , 136b
14. Autoinflammatory Syndrome
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (Suppl) , 136b
14. Autoinflammatory Syndrome
- 31 October 2011
- Vol. 29 (5) , 811-5
Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
To determine whether soluble urokinase plasminogen activator receptor is a useful biomarker to predict the response to adalimumab (ADA) in Japanese patients with rheumatoid arthritis. Rheumatoid arthritis (RA) patients administrated ADA (n=51) were classified as good responders (n=18) or nonresponders (n=9) according to the EULAR response criteria after 8 weeks of bi-weekly ADA administration. We examined the expression of cytokines and chemokines in these groups by antibody array methods. Positive results obtained by antibody array methods were further confirmed by ELISA. Antibody array has identified that the macrophage migration inhibitory factor (MIF), vascular endothelial growth factor (VEGF) and soluble urokinase plasminogen activator receptor (uPAR) decreased in the good responders to ADA whereas these changes were not observed in the non-responders. The decrement of serum uPAR was confirmed by ELISA in the good responders to ADA. Furthermore, serum uPAR at baseline was significantly high in non-responders compared with good responders. An antibody array is convenient for screening the expression of proteins of interest. Examination of serum uPAR at baseline and thereafter may be useful as a predictive biomarker for primary failure toward ADA in patients with RA.
- 31 October 2011
- Vol. 29 (5) , 811-5
Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
To determine whether soluble urokinase plasminogen activator receptor is a useful biomarker to predict the response to adalimumab (ADA) in Japanese patients with rheumatoid arthritis. Rheumatoid arthritis (RA) patients administrated ADA (n=51) were classified as good responders (n=18) or nonresponders (n=9) according to the EULAR response criteria after 8 weeks of bi-weekly ADA administration. We examined the expression of cytokines and chemokines in these groups by antibody array methods. Positive results obtained by antibody array methods were further confirmed by ELISA. Antibody array has identified that the macrophage migration inhibitory factor (MIF), vascular endothelial growth factor (VEGF) and soluble urokinase plasminogen activator receptor (uPAR) decreased in the good responders to ADA whereas these changes were not observed in the non-responders. The decrement of serum uPAR was confirmed by ELISA in the good responders to ADA. Furthermore, serum uPAR at baseline was significantly high in non-responders compared with good responders. An antibody array is convenient for screening the expression of proteins of interest. Examination of serum uPAR at baseline and thereafter may be useful as a predictive biomarker for primary failure toward ADA in patients with RA.
- 6 September 2011
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 22 (2) , 195-201
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors
We aimed to investigate whether delayed treatment with tumor necrosis factor (TNF) inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs (DMARDs) was effective among patients with very early rheumatoid arthritis (RA) with poor prognosis factors. We examined 22 patients with very early RA who were positive for anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. The mean disease duration at entry was 14.1 weeks. A treat-to-target strategy, aiming at simplified disease activity index (SDAI) remission, was initiated with synthetic DMARDs. SDAI remission was not achieved in 9 of the 22 patients with synthetic DMARDs alone, and TNF inhibitors were added in these patients. SDAI values in these 9 patients were further examined for the following 6 months. The TNF inhibitors (infliximab 8, etanercept 1) were added at a mean interval of 34.1 weeks after the initiation of synthetic DMARDs. SDAI remission was achieved in 4 of the 9 patients (44.4%) at 3 months and in 8 of the 9 patients (88.9%) at 6 months after the introduction of the TNF inhibitors. Radiographic damage had not progressed in these patients. Delayed treatment with TNF inhibitors is effective and tolerable for patients with very early RA with poor prognosis factors.
- 6 September 2011
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 22 (2) , 195-201
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors
We aimed to investigate whether delayed treatment with tumor necrosis factor (TNF) inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs (DMARDs) was effective among patients with very early rheumatoid arthritis (RA) with poor prognosis factors. We examined 22 patients with very early RA who were positive for anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. The mean disease duration at entry was 14.1 weeks. A treat-to-target strategy, aiming at simplified disease activity index (SDAI) remission, was initiated with synthetic DMARDs. SDAI remission was not achieved in 9 of the 22 patients with synthetic DMARDs alone, and TNF inhibitors were added in these patients. SDAI values in these 9 patients were further examined for the following 6 months. The TNF inhibitors (infliximab 8, etanercept 1) were added at a mean interval of 34.1 weeks after the initiation of synthetic DMARDs. SDAI remission was achieved in 4 of the 9 patients (44.4%) at 3 months and in 8 of the 9 patients (88.9%) at 6 months after the introduction of the TNF inhibitors. Radiographic damage had not progressed in these patients. Delayed treatment with TNF inhibitors is effective and tolerable for patients with very early RA with poor prognosis factors.
- Open Access
- 1 July 2010
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 11 (1) , 140
Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study
To clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-centromere antibody (ACA).
- 1 July 2010
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 11 (1) , 140
Open AccessAnti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study
To clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-centromere antibody (ACA).
- 1 July 2009
- Published by Springer Nature in Cytotechnology
- Vol. 60 (1-3) , 161-164
Different expression levels of TNF receptors on the rheumatoid synovial macrophages derived from surgery and a synovectomy as detected by a new flow cytometric analysis
TNFα plays a crucial role in the pathogenesis of rheumatoid arthritis. It is very important to examine the expression of the TNF receptors, the ligand of TNFα. In this study, we developed a triple-color flow cytometric analysis using CD45 and CD14 monoclonal antibodies to simply detect the expression of the TNF receptors on the heterogeneous rheumatoid synovial cells. Using this system, we detected a higher population of macrophages and a greater TNF receptor expression on the synovial macrophages derived from a synovectomy in comparison to the findings obtained from knee joint replacement surgery.
- 1 July 2009
- Published by Springer Nature in Cytotechnology
- Vol. 60 (1-3) , 161-164
Different expression levels of TNF receptors on the rheumatoid synovial macrophages derived from surgery and a synovectomy as detected by a new flow cytometric analysis
TNFα plays a crucial role in the pathogenesis of rheumatoid arthritis. It is very important to examine the expression of the TNF receptors, the ligand of TNFα. In this study, we developed a triple-color flow cytometric analysis using CD45 and CD14 monoclonal antibodies to simply detect the expression of the TNF receptors on the heterogeneous rheumatoid synovial cells. Using this system, we detected a higher population of macrophages and a greater TNF receptor expression on the synovial macrophages derived from a synovectomy in comparison to the findings obtained from knee joint replacement surgery.
- 13 March 2009
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 19 (3) , 245-252
A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis
To elucidate the characterization of peripheral natural killer (NK) cells in patients with rheumatoid arthritis (RA), we investigated the NK cell activity, the expression of NK cell activating rece...
- 13 March 2009
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 19 (3) , 245-252
A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis
To elucidate the characterization of peripheral natural killer (NK) cells in patients with rheumatoid arthritis (RA), we investigated the NK cell activity, the expression of NK cell activating rece...
- 2 October 2007
- Published by Elsevier in Life Sciences
- Vol. 81 (19-20) , 1461-1466
La autoantigen translocates to cytoplasm after cleavage during granzyme B-mediated cytotoxicity
- 2 October 2007
- Published by Elsevier in Life Sciences
- Vol. 81 (19-20) , 1461-1466
La autoantigen translocates to cytoplasm after cleavage during granzyme B-mediated cytotoxicity